Cetya Therapeutics

Founded in 2012 and based in Fort Collins, Colorado, Cetya Therapeutics is developing isoform-selective histone deacetylase inhibitors (HDACi) derived from largazole, a natural product. The company has nominated its lead candidate, CT-101, for the treatment of sickle cell disease, a significant unmet medical need. Cetya has strengthened its leadership with key board appointments and secured intellectual property through a process patent for its novel synthetic route, positioning itself to advance its pipeline.

Proprietary platform for developing novel, isoform-selective histone deacetylase inhibitors (HDACi) based on analogs of largazole, a natural product, with a patented synthetic manufacturing route.

Cetya faces competition in sickle cell disease from approved gene therapies (Vertex/CRISPR, Bluebird Bio) and small molecules (Global Blood Therapeutics, Novartis). In the HDAC inhibitor space, it competes with approved oncology drugs (Merck, Celgene) and other developers. Differentiation hinges on the novel largazole chemistry, isoform selectivity, and expansion into non-oncology indications.